Rajeev Singh Raghuvanshi
Appointed As The New Drug Controller General Of India
DCGI, or Drug Controller General of India, is responsible
for ensuring the supply of quality drugs throughout the
country and holds the authority to approve new drugs as
well as regulate clinical trials. Dr. Raghuvanshi, the new
DCGI, has a strong background in the field with over 250
published patents and 25 publications in peer-reviewed
Rajeev Singh Raghuvanshi,
former Indian Pharmacopoeia Commission
secretary-cum-scientific director has been appointed as
the new Drug Controller General of India (DCGI), Central
Drugs Standard Control Organization (CDSCO).
Raghuvanshi will supersede Dr
PBN Prasad who is holding the said position till February
28. The order which was released on Wednesday stated that
Raghuvanshi will continue to be the DGCI till February 28,
Recently, The Union Public
Service Commission (UPSC) has recommended to the
government his name as the successor to Dr V G Somani,
whose extended tenure will end mid-February, officials
said. The recommendation was later approved by the Health
Ministry, followed by approval of the Appointments
Committee of Cabinet led by Prime Minister Narendra Modi.
“The UPSC on the basis of
assessment of bio-data of the eligible officers
received…and after holding personal talks with them on
January 27 recommend Dr Rajeev Singh Raghuvanshi for
appointment to the post of Drug Controller (India) by
short term contract basis,” according to the UPSC
communication to the Health Ministry.
The DCGI heads the Central
Drugs Standard Control Organisation (CDSCO) which is
responsible for ensuring quality drugs supply across the
country. It also has authority to give approval to new
drugs and regulating clinical trials.
Dr Raghuvanshi has 14 granted
US patents along with more than 250 published patent
cooperation treaties and Indian patents. He has more than
25 publications in peer reviewed journals and has
co-authored six chapters in books.
; Feb 22, 2023
DCGI Calls For Medical
Devices Testing Laboratories To Register With Its Network
The Drug Controller General
of India (DCGI) has directed the laboratories which have
capacity for testing medical devices, with adequate
quality accreditation, to submit applications to
strengthen the medical devices testing laboratories (MDTLs)
network in the country, even as the medical devices are in
the phase of entering the licensing regime.
So far it has more than 28
laboratories registered with the office for testing
purposes. The DCGI's office is receiving the applications
for registration under Medical Devices Rules (MDR), 2017
from various laboratories for testing of different medical
devices, said the regulator.
"In order to enhance the
testing capacity of medical devices in the country,
identification, registration and empanelment of
government, private testing laboratory for medical devices
testing is under consideration as per the MRD 2017," said
a notice issued by V G Somani, DCGI.
regard, the DCGI requested the laboratories which have
capacity for testing medical device and are accredited by
the National Accreditation Board for Testing and
Calibration Laboratories (NABL), a constituent Board of
Quality Council of India, to submit the application in
Form MD-39 along with requisite fees and documents through
online portal for further necessary action.
; December 27, 2022.